Highlights From the Preventive Cardiology Summit: Applying New Options for Optimal CV Risk Management

1.25 CME
75 MINS
$0 FEE
SAVE
Highlights From the Preventive Cardiology Summit: Applying New Options for Optimal CV Risk Management

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals.  


Activity Description

In the United States, cardiovascular disease (CVD) is the leading cause of death, claiming more than 800,000 lives annually. Cardiologists play a significant role in the prevention of CVD via the management of risk factors, yet training in preventive cardiology is inadequate and options for managing CVD risk are expanding rapidly. This CME activity is designed for fellows in cardiology or CVD prevention and other health care professionals to advance their knowledge regarding care of patients with CVD. This monograph Highlights From the Summit for Preventive Cardiology: Applying New Options for Optimal CV Risk Management includes evidence-based guidelines on low-density lipoprotein cholesterol (LDL-C)–lowering treatment to reduce CVD risk in patients with dyslipidemia, as well as the safety and efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The complex relationship between type 2 diabetes mellitus and CVD risk and the importance of managing additional risk factors will also be examined.


Target Audience

The intended audience for the activities is cardiology fellows and other health care professionals involved in the treatment of patients with CVD.


Learning Objective(s)

Upon successful completion of this activity, participants should be better able to:

  • Assess evidence-based LDL-C lowering treatment guidelines to reduce cardiovascular (CV) risk in patients with dyslipidemia. 
  • Review the complex relationship between type 2 diabetes mellitus and CV risk and the importance of managing additional risk factors in these patients. 
  • Evaluate the safety and efficacy of very low LDL-C levels that can be achieved with PCSK9 inhibitors. 
  • Review the methods for advanced lipid testing and genetic screening to better characterize the underlying cause of dyslipidemia and guide clinical decision-making. 
  • Examine appropriate strategies for the management of multiple CV risk factors and implications for polypharmacy.

Activity Chair

Michael H. Davidson, MD, FACC, FACP, FNLA, FASPC
Professor of Medicine
Director of the Lipid Clinic
The University of Chicago Pritzker School of Medicine
Chicago, IL


Faculty

David J. Davidson, MD, FACC
Clinician Educator
NorthShore Medical Group
Evanston, IL

Martha Gulati, MD, MS, FACC, FAHA, FASPC
Professor of Medicine
Chief of Cardiology, University of Arizona College of Medicine - Phoenix
Editor-in-Chief, CardioSmart for The American College of Cardiology
Phoenix, AZ

Carl E. Orringer, MD, FACC, FNLA
Associate Professor of Medicine
Director of Preventive Cardiovascular Medicine
University of Miami Miller School of Medicine
Miami, FL


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 25, 2019, to December 25, 2020.


How to Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty report the following relationship(s)

David J. Davidson, MD, FACC
Consulting Fee: Akcea, Amgen, Regeneron, Sanofi

Michael H. Davidson, MD, FACC, FACP, FNLA, FASPC
Consulting Fee: Amgen, Novo Nordisk, Regeneron, Sanofi
Speakers Bureau: Amgen, Novo Nordisk, Regeneron, Sanofi

Martha Gulati, MD, MS, FACC, FAHA, FASPC
No relevant financial relationships to disclose.

Carl E. Orringer, MD, FACC, FNLA
No relevant financial relationships to disclose

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com